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Here we report on the identification of peptides tar-
geting the X-inhibitor of apoptosis protein (XIAP). XIAP
functions as a caspase inhibitor and is a member of the
inhibitors of apoptosis (IAP) family of proteins. IAPs are
often overexpressed in cancers and leukemias and are
associated with an unfavorable clinical prognosis. We
have selected peptides from a phage library by using
recombinant full-length human XIAP or a fragment con-
taining only the baculovirus IAP repeat 2 (BIR2) do-
main. A consensus motif, C(D/E/P)(W/F/Y)-acid/basic-XC,
was recovered from two independent screenings by us-
ing different libraries. Phage-displaying variations of
the consensus sequence bound specifically to the BIR2
domain of XIAP but not to other IAPs. The interaction
was specific as it could be blocked by the cognate syn-
thetic peptides in a dose-dependent manner. Phage dis-
playing the XIAP-binding motif CEFESC bound to the
BIR2 domain of XIAP with an estimated dissociation
constant of 1.8 nM as determined by surface plasmon
resonance. Protein-protein interaction assays revealed
that caspase-3 and caspase-7 (but not caspase-8) blocked
the binding of the CEFESC phage to XIAP, indicating
that this peptide targets a domain within XIAP that is
related to the caspase-binding site. In fact, the sequence
EFES is homologous to a loop unique to the executioner
caspase-3 and caspase-7 that are targeted by XIAP. Fi-
nally, we demonstrated that an internalizing version of
the XIAP-binding peptide identified in our screenings
(PFKQ) can induce programmed cell death in leukemia
cells. Peptides interacting with XIAP could serve as pro-
totypes for the design of low molecular weight modula-
tors of apoptosis.
The inhibitor of apoptosis proteins (IAPs)1 represent a family
of anti-apoptotic proteins found in both vertebrates and inver-
tebrates (reviewed in Ref. 1). All of the human IAP homologs
have been shown to inhibit programmed cell death (1, 2). The
human IAP family members, XIAP, c-IAP1, and c-IAP2, bind to
caspase-3 and caspase-7 with inhibitory constant values (Ki) of
0.2–10 nM (3–5). XIAP also binds to and suppresses specifically
caspase-9, an initiator caspase, that is at the apical protease in
the cytochrome c/mitochondrial pathway for apoptosis (6–9).
All of the IAP family members have at least one and up to
three copies of an 70-amino acid zinc-binding domain termed
the baculovirus IAP repeat (BIR) (1). We have performed mu-
tagenesis-based studies to show that in the context of XIAP, the
second of the three BIR domains (BIR2) is necessary and suf-
ficient to inhibit the effector proteases caspase-3 and caspase-7
(10). In contrast, for XIAP to suppress caspase-9, the third BIR
domain is required (11). These data suggest that a single BIR
domain can mediate anti-apoptotic activity. To map function-
ally relevant interacting sites within molecules associating
with XIAP, we screened peptide libraries using the full-length
protein and on the isolated BIR2 domain.
We identified XIAP ligands containing the motif CEFESC.
This motif appears to mimic the XIAP-binding site within
specific caspases because the binding of this peptide to XIAP is
inhibited by preincubation with caspase-3 and caspase-7 but
not by caspase 9. Binding assays using individual phage dis-
playing this motif and a panel of purified targets confirmed
that the phage interacts specifically with the BIR2 domain in a
pattern consistent with caspase-type ligands. No binding was
observed when BIR1, BIR3, or the RING finger domain of XIAP
were tested nor when other IAP family members such as cIAP1,
cIAP2, NAIP, and Survivin were evaluated under the same
experimental conditions. We also show that XIAP-binding pep-
tides can affect cell viability. Taken together, our results con-
tribute to the understanding of the structural requirements
and functional domains that are important in the regulation of
programmed cell death.
EXPERIMENTAL PROCEDURES
Plasmids, Protein Expression, and Purification—Cloning and syn-
thesis of full-length XIAP and the XIAP fragments BIR1, BIR2, BIR3,
BIR1–2, BIR2–3, and RING as well as full-length cIAP1, cIAP2, NAIP,
and Survivin have been described previously (4, 10, 12). Recombinant
caspase proteins containing His6 tags were prepared as described pre-
viously (8) and were a gift from Dr. G. Salvesen (The Burnham Insti-
tute, La Jolla, CA).
Identification of XIAP-binding Peptides by Phage Display—fUSE5-
based phage peptide libraries displaying either cyclic or linear random
peptides (CX4C or X6; C  cysteine and X  random amino acid) were
made and screened as described previously (13, 14). Polystyrene 96-well
plates were coated with 50 l/well of 1 mg/ml GST-XIAP fusion protein
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or GST fusion proteins of various fragments of XIAP, cIAP1, cIAP2,
NAIP, Survivin, BSA, or GST in PBS overnight at 4 °C. The wells were
washed with PBS, blocked with 3% BSA (first round of panning), casein
(second round), or -globulins (third round) for 1 h, and incubated with
1010 transducing units (TU) of the primary library for 1 h at room
temperature. The wells were washed nine times in PBS, 0.01% Tween
20 to remove unbound phage and once with PBS. Bound phages were
eluted by adding 200 l of a log-phase K91Kan terrific broth culture and
amplified overnight in 10 ml of LB medium containing 40 g/ml tetra-
cycline. Randomly selected phage clones from the third round of pan-
ning were sequenced as described previously (15). Individual phage
clones displaying similar peptide motifs were tested for specific binding
to GST fusion proteins of XIAP, fragments of XIAP, cIAP1, cIAP2,
NAIP, Survivin, BSA, or GST alone. These binding assays were per-
formed following the protocol of the initial screening. The number of
bound phage was determined by plating serial dilutions of the recovered
phage-bacteria mixture on LB agar plates containing 40 g/ml
tetracycline.
Peptide Synthesis—Peptides were synthesized with an ACT-350 mul-
tiple peptide synthesizer by using Fmoc synthesis on Rink amide
MBHA resin or Fmoc-Lys(-LC-D-Biotin)-Rink amide-MBHA resin for
C-terminally biotinylated peptides. The peptides were cleaved with
92.5% trifluoroacetic acid, 2.5% water, 2.5% EDTA, and 2.5% TIS and
precipitated with cold ethyl ether. Quantitative cyclization was
achieved in 20% Me2SO, H2O, pH 4.0–7.0 in 1 day as described previ-
ously (16). Crude peptides were purified by high pressure liquid chro-
matography on a reverse phase C-18 column with a gradient of water/
acetonitrile containing 0.1% trifluoroacetic acid. The purified peptides
showed one peak by analytical high pressure liquid chromatography,
and the molecular weight was confirmed by matrix-assisted laser des-
orption ionization time-of-flight mass spectroscopy.
Caspase Competition Assays—Inhibition of phage binding to XIAP by
recombinant caspases was assayed by coating polystyrene 96-well
plates with 1 g/well of recombinant XIAP protein (50 l of a 1 mg/ml
solution), various fragments of XIAP, or control proteins (as indicated)
in PBS overnight at 4 °C. The wells were washed once with PBS,
blocked with 3% BSA for 1 h, washed again, and incubated with various
amounts of recombinant active caspases-3, -7, or -8 for 30 min at room
temperature. The wells were then washed once with PBS, and XIAP-
binding or control phage was added (108 TU/well) and incubated for 30
min. Wells were then washed nine times with PBS, 0.01% Tween 20,
and washed once more in PBS. Bound phage were eluted by adding 200
l of a log-phase K91Kan terrific broth culture. The number of bound
phage was determined as described above.
Surface Plasmon Resonance—The interaction of XIAP-binding phage
and control phage with the BIR2 domain of XIAP was investigated
using the BIAcore 3000 system (BIAcore, Uppsala, Sweden). GST-BIR2
was covalently attached by its primary amine residues to CM5 sensor
chips (17). Binding was detected in resonance units after injecting
phage in a range of concentrations in HBS buffer (10 mM HEPES, pH
7.4, with 0.15 M NaCl, 3.0 mM EDTA, and 0.05% surfactant P20). After
each run, the chip surfaces were regenerated with 10 mM glycine, pH
4.5. Non-linear regression analysis was used to determine equilibrium-
binding constants that fit to a single site-binding model (18–20).
Peptide Internalization and Cell Viability Assays—Uptake of pen-
etratin-linked peptides into OCI/AML-4 cells (an acute myeloblastic
leukemia cell line, for review see Ref. 21) was monitored as described
previously (22). Cells growing in 24-well plates were incubated with
increasing doses (1–20 M) of penetratin alone, synthetic peptides alone
(CEFESC, CPFKQC, or ARGKER), or penetratin-linked versions of
each peptide. Cell viability was assessed at different time points (12, 24,
and 72 h).
RESULTS
Identification of XIAP-binding Peptides—XIAP-binding pep-
tides were identified by selecting phage display peptide librar-
ies on immobilized human GST-XIAP. The libraries contained
six amino acid inserts in which either all six residues were
randomized or the first and last positions were fixed as cys-
teines to promote cyclization by disulfide bonding (X6 or CX4C
libraries, respectively). The enrichment of phage on XIAP was
monitored by counting the number of TU recovered from the
XIAP-coated wells versus the number recovered from wells
coated with the control protein. We observed a pronounced
enrichment for phage binding to GST-XIAP (Fig. 1). The DNA
inserts of 36 randomly chosen phage clones (18 from the X6
library and 18 from the CX4C library) recovered from the third
round of biopanning on XIAP were sequenced. A total of 32
phage clones derived from both libraries displayed the consen-
sus motif C-(E/D/P)-(aromatic amino acid  W/Y/F)-charged
amino acid-(X  random)-C (Table I). In addition, marked
enrichment was observed for phage displaying the motif (8 of
18 in the second round and 16 of 18 in the third round by using
the X6 library). In contrast, biopanning experiments using the
same libraries on other IAPs such as Survivin or on GST
protein alone failed to select for phage with the above consen-
FIG. 1. Enrichment of XIAP-binding phage on recombinant
XIAP. A CX4C random phage-display peptide library was selected on
immobilized GST-XIAP as described under “Experimental Procedures.”
Aliquots of the recovered phage-bacteria mixture were plated on LB
plates containing tetracycline to determine the number of TU recov-
ered. Data represent the number of TU recovered from wells coated
either with GST-XIAP (black bars) or a control protein (white bars;
casein for screening round II, bovine -globulins for screening round
III).
TABLE I
Sequences of XIAP-binding peptides
Randomly selected phage clones displaying the XIAP-binding motif
were grouped into three subsets based on the amino acid residue at
position 2.
C D W T H C
C D W R V C
C D W L T C
C D W L T C
C D W L T C
C D W N Q C
C D F I M C
C D W V F C
C D F K A C
C D F V G C
C E Y K E C
C E E N L C
C E F L F C
C E F F F C
C E K F P C
C E F A Q C
C E F A Q C
C E H Y P C
C E F E S C
C P F I R C
C P F T E C
C P F D R C
C P Y R H C
C P F M A C
C P F K E C
C P F H T C
C P Y K Q C
C P F K Q C
C P F A A C
C P Y H E C
C P Y R R C
C P Y R F C
Motif: C D/E/P Aromatic / X C
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sus motif, demonstrating the specificity of the selection process.
Phage Specificity and Mapping of Binding Sites on XIAP—
The specificity of XIAP-binding phage was tested in individual
phage-binding assays on immobilized GST-XIAP or GST fusion
proteins of other members of the IAP family such as Survivin,
cIAP1, cIAP2, and NAIP. Representative data are shown for
two of the XIAP-binding phage displaying the CEFESC- or the
CPFKQC-peptide. Controls were insertless fd-tet phage and
phage-displaying ARGKER, an unrelated control insert. In
these assays, both the CEFESC and CPFKQC phage bound to
XIAP but not to the other IAP family members, BSA, or GST.
Control phage did not bind to GST-XIAP, indicating specificity.
These data confirm the specificity of phage clones displaying
the consensus motif for XIAP binding (Fig. 2).
We next mapped the domain within XIAP that mediates the
binding of the isolated phage clones using a panel of XIAP
deletion mutants expressed as GST fusion proteins. XIAP-
binding phage bound to GST fusion proteins containing the
BIR2 domain of XIAP alone or the BIR2 domain in combination
with flanking domains. In contrast, fragments of XIAP contain-
ing only the BIR1, BIR3, or RING domains failed to adsorb
XIAP-binding phage. The insertless fd-tet phage as well as the
control ARGKER-phage did not bind to either GST-XIAP or
FIG. 2. CEFESC and CPFKQC selec-
tively bind to XIAP but not to other
IAP family members. Phage displaying
no peptide insert (fd-tet), the XIAP-bind-
ing sequences CEFESC or CPFKQC, or a
control sequence ARGKER were incu-
bated in microtiter plate wells coated
with 2 g of various GST fusion proteins
(XIAP, Survivin, cIAP1, cIAP2, and
NAIP), GST alone, or BSA. Bound phage
were recovered by bacterial infection.
Transduced bacteria were grown over-
night on LB plates containing tetracycline
to determine the number of TU recovered.
Data are expressed as the percentage rel-
ative to the number of TU recovered from
wells coated with GST-XIAP (set to
100%). Data represent the means from
triplicate platings  S.D.
FIG. 3. XIAP-binding phage interact
with the BIR2 domain of XIAP. Phage
were incubated in microtiter plate wells
coated with 2 g of immobilized GST fu-
sion proteins representing full-length
XIAP, various fragments of XIAP, or BSA
(control). Bound phage were rescued and
quantified by colony counting as in Fig. 2.
FIG. 4. Synthetic peptides displaying phage-derived se-
quences bind XIAP. Binding of CEFESC phage to XIAP is inhibited
by the cognate peptide. Binding of phage displaying the XIAP-binding
peptide-CEFESC or a control peptide (ARKGER) to GST-XIAP or GST-
BIR2 was measured as in Fig. 2 in the presence or absence of cyclic
CEFESC-synthetic peptide. Data represent the means from triplicate
platings  S.D. and are expressed as the percentage relative to the
number of TU obtained in the absence of synthetic peptides.
FIG. 5. Surface plasmon resonance characterizes the binding
of the CEFESC-phage to the BIR2 domain of XIAP. Recombinant
BIR2 of XIAP was immobilized on a sensor chip, and a range of con-
centrations of CEFESC phage was injected over the chip surface. Data
represent resonance units plotted as a function of time. The arrow
indicates the time at which the mobile phase was switched to the buffer
lacking phage. The binding constant (KD) was estimated from associa-
tion and dissociation rate constants using sensograms analyzed by
Bioevaluation 3.0 (BIAcore) software.
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GST-BIR2, indicating that the target proteins do not bind
recombinant phage nonspecifically (Fig. 3).
Synthetic Peptides Representing Phage-derived Sequences
Bind XIAP—To further confirm that the peptides displayed on
XIAP-binding phage interact with XIAP independently of other
phage components, experiments were performed using syn-
thetic peptides. Cyclic peptides corresponding to the sequences
displayed by XIAP-binding phage clones were synthesized and
tested for their ability to specifically inhibit phage binding to
GST-XIAP and GST-BIR2. The cyclic peptides but not the
irrelevant control peptides inhibited phage binding of the cor-
responding phage clones in a concentration-dependent manner
(Fig. 4). Non-cyclic versions of the same peptides failed to
prevent phage binding.
Binding Properties of XIAP-binding Phage—To further char-
acterize the interaction of XIAP-binding phage with the BIR2
domain, we used surface plasmon resonance. The BIR2 domain
of XIAP was conjugated to the chip surface (solid phase) and
phage displaying a XIAP-binding peptide were used as an
analyte (mobile phase). A variety of concentrations of phage
displaying CEFESC, CPFKQC, or CDFKAC were injected, and
the CEFESC-phage clone was the strongest binder of the three
phages analyzed (Fig. 5). This phage bound to BIR2 with an
estimated ka of 4.9  10
5 M1s1. Upon switching to phage-free
flow solution, a very slow dissociation of phage from the chip
surface was observed with an approximate kd of 8.6  10
4. A
KD of 1.8 nM was estimated for binding of the CEFESC-phage
to BIR2 as compared with a KD of 10 M for either insertless
fd-tet phage or phage displaying a control peptide-ARGKER.
XIAP-binding Phage and Caspases Compete for Binding to
XIAP—Because the BIR2 domain of XIAP has been shown to be
necessary and sufficient for binding caspases-3 and -7 (10), we
asked whether these caspases compete with XIAP-binding
phage for binding to XIAP. GST-BIR2 or various GST control
proteins were immobilized on glutathione-Sepharose and incu-
bated with XIAP-binding CEFESC-phage in the presence or
absence of recombinant caspase-3 or -7. Recombinant caspase-8
was used as a control because it does not bind XIAP (3). The
binding of CEFESC-phage to BIR2 was inhibited in a concen-
tration-dependent manner upon the addition of caspase-7 or
caspase-3. In contrast, neither BSA nor caspase-8 blocked the
binding of CEFESC-phage to XIAP (Fig. 6). These data suggest
that phage displaying the CEFESC-peptide occupy sites on the
BIR2 domain that overlap with or are adjacent to sites involved
in caspase binding.
To determine whether the XIAP-targeting peptides could
affect cell viability, we designed and synthesized internalizing
versions of the CEFESC-, CPFKQC-, or ARGKER-peptides
(negative control) by using the penetratin system for intracel-
lular delivery. Penetratin (Pen) is a peptide containing 16
amino acids that is part of the third helix of the antennapedia
protein homeodomain (22). Because penetratin has translocat-
ing properties, it is capable of carrying hydrophilic compounds
across the plasma membrane and delivering them directly to
the cytoplasm without degradation (22). We fused the XIAP-
binding peptides or a control unrelated peptide to penetratin
and added a biotin moiety to visualize internalization. We used
leukemia cells (OCI/AML-4) as a model system to test the effect
of the internalizing peptides because these cells (i) express
XIAP and caspases and (ii) respond to regulators of apoptosis
(21). Pen-linked peptides were internalized and remained in
the cytoplasm (data not shown). Penetratin alone was also
internalized and uniformly distributed in the cytoplasm. Pep-
tides lacking penetratin were not internalized (data not
shown). We evaluated cell survival in the cells exposed, inter-
nalizing versions of the XIAP-binding peptides. After a 72-h
incubation, reduced cell viability was observed in cells treated
with Pen-CPFKQC (Fig. 7). No cell death was observed when
cells were untreated, treated with penetratin alone, or treated
with an unrelated control peptide fused to penetratin. More-
over, incubation with non-internalizing versions of each syn-
thetic peptide had no effect (Fig. 7).
DISCUSSION
IAPs are overexpressed in a variety of cancers and leuke-
mias, and antagonistic small molecules could be useful for
modifying the antiapoptotic activity of XIAP in vivo. In this
study, we screened phage-display peptide libraries in search of
short peptide motifs capable of binding this caspase-inhibitory
protein. An analysis of the peptides displayed by phage binding
to XIAP revealed a consensus sequence in which position 1 is
invariably a cysteine, position 2 is either an acidic residue
(aspartic acid or glutamic acid) or a proline, and position 3 is
FIG. 6. Caspase-7 but not caspase-8 inhibits binding of phage
to XIAP. GST-XIAP or GST alone were immobilized on microtiter plate
wells (100 ng/well) and incubated with recombinant caspase-7 or
caspase-8 (control) in a total volume of 50 l at the indicated concen-
trations. XIAP-binding CEFESC-phage were added at 107 TU/well and
incubated for 1 h, and bound phage were recovered after washing.
Recovered phage were quantified as in Fig. 2.
FIG. 7. An internalizing version of the XIAP-binding peptide
triggers cell death. Internalization of Pen-CPFKQC leads to growth
arrest and induces programmed cell death in OCI/AML-4 cells. Cell
viability (%) was evaluated at 72 h after no treatment (No peptide) or
incubation with multiple peptides as indicated. Pen-CPFKQC de-
creased cell viability. *, p  0.01. Shown are mean  S.E. obtained from
triplicate wells.
XIAP-binding Peptides14404
usually an aromatic amino acid (tryptophan, phenylalanine, or
tyrosine) followed by two variable amino acids and finally a
cysteine. Although position 4 was variable among the XIAP-
binding phage randomly sequenced, the most highly repre-
sented types of amino acids at position 4 were charged (lysine,
arginine, histidine, aspartic acid, or glutamic acid in 13 of 32
cases). The binding of these phage to XIAP was highly selective
with no evidence of significant interactions with other mem-
bers of the IAP family of proteins such as cIAP1, cIAP2, NAIP,
or Survivin. Thus, the XIAP-binding phage recognize a binding
site unique to XIAP, which may be exploitable for applications
aimed either at detecting XIAP or selectively inhibiting XIAP
function.
We showed that the isolated peptides bind to the BIR2 do-
main of XIAP. The specificity of the motif for BIR2 was con-
firmed independently by repeating library screenings using
GST-BIR2 as a target, resulting in the selection of phage whose
inserts shared the same consensus sequence, which was ob-
tained originally using GST full-length XIAP. Interactions of
these peptide motifs with BIR2 are biologically relevant, be-
cause our previous studies indicate that the BIR2 domain is
necessary and sufficient for inhibiting caspases-3 and -7 (10).
Functional studies using the cyclic XIAP-binding peptides
show that these probes do not act as repressors of XIAP-medi-
ated caspase inhibition. We also show that an internalizing
version of the XIAP-binding peptide identified in our screen-
ings (PFKQ) can induce programmed cell death in leukemia
cells in a specific, dose-dependent, and time-dependent man-
ner. These findings suggest that development of peptidomimet-
ics following affinity maturation strategies to increase binding
affinity may lead to tools that can be used as modulators of
programmed cell death.
During programmed cell death, effector caspase zymogens
are cleaved at conserved aspartic acid residues, generating
large and small subunits, which together constitute the active
protease. The activation of effector caspases such as caspases-3
and -7 is a nearly universal event associated with apoptosis
induced by multiple stimuli. Our previous observation that
XIAP and other IAP family proteins directly bind active execu-
tioner caspases-3 and -7, resulting in their potent suppression
in vitro and in cultured cells (3, 4), suggests a general mecha-
nism for IAP-mediated apoptosis inhibition. Recently, a natu-
rally occurring IAP inhibitor termed Smac/DIABLO has been
identified (23, 24). Smac performs a critical function in apo-
ptosis by eliminating the inhibitory effect of IAPs on caspases.
Smac promotes not only the proteolytic activation of pro-
caspase-3 but also the enzymatic activity of mature caspase-3,
both of which depend upon the ability of Smac to interact
physically with IAPs. A seven-residue peptide derived from the
N terminus of Smac promotes procaspase-3 activation in vitro
(23). Although the amino acid sequence of this peptide is dif-
ferent from our sequences, identification of Smac and Omi
provides further evidence that inhibition of IAPs by peptides
represents a viable approach to induction of apoptosis in mam-
malian cells.
Interestingly, the sequence EFES, which is embedded in one
of the XIAP-binding phage in a cyclic context (CEFESC), occurs
in caspase-3, a protease that binds to BIR2 of XIAP with a KD
5 nM (10). This sequence is located in the 381-loop of
caspase-3 in a region only found in caspases-3 and -7. Because
this loop is important in the binding of BIR2 to caspases-3 and
-7 (5, 25, 26) (for review see Ref. 27), one might speculate that
the EFES-containing peptide corresponds to an important re-
gion within the caspase-3-XIAP interacting site. In fact, the
recently reported x-ray crystallographic structure of the XIAP-
BIR2 domain/caspases-3 and -7 complex shows that the sub-
strate-binding pocket within these caspases is formed by four
surface loops, L1, L2, L3, and L4 (5, 25, 26). The sequence
EFES is exposed for binding within the 381-loop, and the
second Glu residue in the sequence corresponds to an interac-
tion site between caspase-3 and BIR2 (5). This observation
underscores the power of phage display technology for the
mapping for biologically relevant protein-interacting sites.
Although XIAP is widely expressed, abnormally high levels
of XIAP have been observed in certain types of leukemias and
solid tumors (28). Overexpression of XIAP has also been shown
to render tumor cells more resistant to apoptosis induction by
anti-cancer drugs in vitro (2). Thus, agents that interfere with
XIAP activity may be useful to treat cancers. The phage-de-
rived peptides described here could provide a starting point for
the generation of small molecule compounds that bind to and
inhibit XIAP, thereby providing a new approach to the treat-
ment of malignancies. Alternatively, cell membrane-penetrat-
ing versions of XIAP-binding peptides or tumor-targeted deliv-
ery of genes expressing XIAP-binding peptides fused to
ubiquitin ligases could potentially be exploited as mechanism-
based strategies for improved cancer treatment.
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